Pharmacy & Therapeutics/Drug Utilization Review Committee

October 13, 2026
8:00 AM-12:00 PM

Virtual option:
Microsoft Teams meeting
Join: https://teams.microsoft.com/meet/279218711877789?p=QQkKpgBwpezOLprE4e
Meeting ID: 279 218 711 877 789
Passcode: x9F3U8

Dial in by phone
+1 505-312-4308,,383340118# United States, Albuquerque
(888) 506-1357,,383340118# United States (Toll-free)
Find a local number
Phone conference ID: 383 340 118#

DRAFT

Agenda Item	Leader
Welcome	K. Ryan
Approval of Agenda (Attachment A)	K. Ryan
Roll Call of P&T Members	E. Ortega
Acknowledgments/Thank you – A. Bachyrycz & C. Bonham	K. Ryan
Approval of Minutes from July 29, 2026 (Attachment B)	K. Ryan
State Updates • Turquoise Claims • Provider Enrollment • Discussion of Standard Operating Procedures (SOP)	K. Ryan

Closed Session - PDL Class Review & Voting	K. Ryan
Break	
Open Session	
Drug Class Review (Attachment C) Proposed New Drug Classes • Anticonvulsants • Erythropoiesis-Stimulating Agents New to Market Medications • Antipsychotics • Cytokine and CAM Antagonists • Ophthalmic Anti-inflammatories Established Drug Classes with proposed additions: • Antidepressants – Other • Antihistamines – Minimally Sedating • Antihypertensives – Sympatholytic • Anxiolytics • Bronchodilators, Beta Agonist • Glucocorticoids – Inhaled - Public Comment: Regina Swisher -oral • Intranaslal Rhinitis Agents • NSAIDS • Ophthalmic Antibiotics • Ophthalmic Antibiotic/Steroid Combinations • Ophthalmic Agents for Allergic Conjunctivitis • Ophthalmic Glaucoma Agents and Related Agents • Otic Antibiotics • Topical Steroids – Very High Potency • Topical Steroids – High Potency Classes with No Proposed Changes: • Antidepressants – SSRIs • Antihyperuricemics • COPD Agents • Epinephrine – Self-Administered • Histamine ll Receptor Blockers • Immunomodulators – Asthma • Immunomodulators – Atopic Dermatitis • Leukotriene Modifiers • Movement Disorders • Ophthalmic Dry Eye Agents	Prime

DRAFT

• Smoking Cessation • Topical Steroids – Low Potency • Topical Steroids – Medium Potency Addendum • Antiemetic/Antivertigo Agents • Generous Offers	
HCA Administrative Updates • GLP-1 drug criteria for non-diabetes indications and for EPSDT population for weight reduction (Vote needed) (Attachment D) • Change in prior authorization approval duration to 3 years for maintenance medications • GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) model discussion • Gender-Affirming Care (GAC) drug edit/criteria • Recruitment of Committee Members	K. Ryan/ J. DiTucci-Reiter /L. Meskin/ B. Ninan
Open Comments	Prime/K. Ryan
ProDUR (Attachment E)	Conduent
RetroDUR (Attachment E)	Conduent
Quarterly reports (Attachment E)	Conduent
Upcoming Interventions (Attachment E)	Conduent
Adjournment	K. Ryan

DRAFT